Peli BioThermal Expands Global Rental Network in Incheon, South Korea

The new drop point and network station will service Crēdo™ on Demand reusable shipping containers as South Korea positions itself as a major pharmaceutical hub

Credo Cargo

Peli BioThermal, leading global provider of temperature-controlled packaging, has announced the opening of a new network station and drop point in Incheon, South Korea—as the country eyes pharmaceutical development as a primary driver of economic growth. This network station is strategically located near the capital city of Seoul to enable the region to take advantage of the Crēdo™ on Demand rental option for temperature-controlled containers.

Dominic Hyde“South Korea is a significant player in the development of generic pharmaceuticals, and it’s already home to 40-plus multinational pharmaceutical companies,” said Dominic Hyde, Vice President of Crēdo on Demand at Peli BioThermal. “Having access to a high performance, flexible rental option for shipping temperature-sensitive pharmaceuticals can expand South Korea’s reach throughout Asia and beyond.”

GlobalData reports that South Korea’s pharmaceutical market is expected to climb to $23.3 billion by 2022. According to the Korean Ministry of Food and Drug Safety, pharmaceutical exports have experienced double-digit annual growth in recent years — due to increased shipments to Europe, Asia, and North America.

The new drop point and network station joins more than 100 locations across the globe supporting Peli BioThermal’s Crēdo™ on Demand rental program. The Incheon location will service, refurbish, repair, and condition Peli BioThermal’s reusable Crēdo™ Cargo and Crēdo Xtreme™ shipping containers. 

 Visit www.pelibiothermal.com to learn more about the wide range of Peli BioThermal products and offerings. 

Peli BioThermal is a division of Peli Products, S.L.U., which is the European arm of Pelican Products, Inc., which is a portfolio company of Behrman Capital, a private equity investment firm based in New York and San Francisco.